Amanta Healthcare Ltd
AMANTAAmanta Healthcare Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the P/E sits at the 81st percentile of its own range — the multiple has already done part of the work.
The price is in a confirmed uptrend (13 weeks in) while the P/E sits at the 81st percentile of its own 1-year range. Underneath, the last four quarters read deteriorating — profit −5.7% year on year, and 528% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Amanta Healthcare Ltd trades at ₹156, in a confirmed uptrend and 13 weeks into that stage. That is +13.9% against its own 200-day average. It sits at 73% of a 52-week range of ₹96 to ₹179. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 27 straight weeks.
Today the stock is in a confirmed uptrend — week 13 of stage 2, confirmed. At ₹156 it trades +13.9% versus its 200-day average and sits at 73% of its 52-week range (₹96–₹179).
Against the market, two honest reads. Cumulative: over the last 11 months the stock moved +12% while the NIFTY 500 moved +1% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 27 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Amanta Healthcare Ltd trades at 39.6× P/E, at the pricey end of its own range (81st percentile). Its long-run median P/E is 33.6×, measured across 0.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 39.6× is at the pricey end of its own range (81st percentile), against a long-run median of 33.6× measured over 0.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +5.2% against a +11.8% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
At its price on 13 June 2026, Amanta Healthcare Ltd was priced for profit growth of about 22.7% a year. The market pays that at 39.6× P/E, the 81st percentile of its own 1-year range.
What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is the whole of what a buyer is backing. Both readings sit on the same earnings, so they are one reading rather than two.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements. Every other number on this page is read off the live quote.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Amanta Healthcare Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 5 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +4.7% | +3.6% | +11.0% | — |
| Profit | +50.0% | — | — | — |
| EPS | +5.2% | — | — | — |
| Share price | +11.8% | — | — | — |
4-Factor Sector Score
39.1/100 — rank 2 of 2 in Pharmaceuticals Bulk Drugs & Formulation · 57% evidence confidence
Amanta Healthcare Ltd scores 39.1 out of 100 against the 2 companies it is compared with in Pharmaceuticals Bulk Drugs & Formulation, ranking 2. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 5.9 + 13.2 + 10 + 10 = 39.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Amanta Healthcare Ltd reported ₹68.8 Cr of revenue in the Jun 26 quarter, +5.3% year on year. That is the 4th straight quarter of year-on-year growth. Over 6 years it has compounded at 7.8% a year. The last full year, FY26, came in at ₹288 Cr. The last four reported quarters add to ₹291 Cr.
FY26 revenue came in at ₹288 Cr (+4.7% on the year), capping 6 years at 7.8% compound. The latest quarter (Jun 26) printed ₹68.8 Cr, +5.3% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +7.1% growth against the decade's 7.8% — the current year is running in line with its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Amanta Healthcare Ltd's operating margin is 21.1% in the Jun 26 quarter, −1.7 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 20.0% to 23.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 21.1%, −1.7 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 20.0%–23.0%.
🚨 Why the margin moved: operating margin went −1.7 pp year on year while gross margin went −2.3 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Amanta Healthcare Ltd earned ₹3.3 Cr of net profit in the Jun 26 quarter, −5.7% year on year. Full-year FY26 profit was ₹15.0 Cr. That is 4.8% of the quarter's revenue. The same quarter a year earlier earned ₹3.5 Cr. 1 of the last 9 reported quarters were loss-making.
Jun 26 profit was ₹3.3 Cr, −5.7% year on year. On the full year, FY26 printed ₹15.0 Cr (+50.0%).
🚨 Why profit moved: revenue contributed +5.3% and the margin −1.7 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit −12.8% vs revenue +7.1%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 528% of Amanta Healthcare Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹48.0 Cr of operating cash against ₹15.0 Cr of profit. After ₹84.0 Cr of capital spending, ₹−36.0 Cr was left as free cash.
FY26: operating cash of ₹48.0 Cr against reported profit of ₹15.0 Cr, leaving free cash of ₹−36.0 Cr after ₹84.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 528% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 528%: the cash cycle tightened 114 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 1.8× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Amanta Healthcare Ltd's cash conversion cycle runs 231 days in FY26, down from 345 days in FY21. Capital spending ran ₹105 Cr over the last 3 years. At FY26 sales of ₹288 Cr each day of that cycle holds about ₹0.8 Cr, so roughly ₹182 Cr sits inside the business at any moment.
FY26: debtors at 55 days, inventory at 312 days — roughly 10.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 231 days, tighter than FY21's 345.
The full loop: cash goes out to suppliers and production on day 0; stock waits 312 days to sell; customers pay about 55 days after that; and suppliers themselves are paid at 136 days — netting out to the 231-day cycle.
In money terms: at FY26 sales of ₹288 Cr, each day of the cycle holds about ₹0.8 Cr — so the 231-day loop keeps roughly ₹182 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹105 Cr over the last 3 fiscal years against ₹57.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹82.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Amanta Healthcare Ltd earns a ROCE of 12% in FY26. That is up from a trough of 9% in FY21. Return on invested capital clears the cost of that capital by −3.3 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 5.2% net margin on 0.52× asset turns.
FY26 ROCE is 12%, recovered from a FY21 trough of 9% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 5.2% net margin × 0.52× asset turns × 2.54× balance-sheet leverage ≈ 6.9% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 8.7% − 12.0% = a −3.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Amanta Healthcare Ltd carries total debt of ₹244 Cr against shareholder equity of ₹220 Cr as of Mar 26, a debt-to-equity of 1.11. On the annual view that ratio went from 2.13 in FY25 to 1.11 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹244 Cr against shareholder equity of ₹220 Cr — a debt-to-equity of 1.11. On the annual view, debt-to-equity went from 2.13 (FY25) to 1.11 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Amanta Healthcare Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Amanta Healthcare Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Alivus Life Sciences LtdALIVUS | 72.5/100Favorable setup97% evidence | LEADER | 22.6/35 Revenue 7.9% · PAT 21.6% · OPM change 4 pp 100% evidence | 20.0/25 ROCE 23.8% · OPM 33% 100% evidence | 11.2/20 P/E 27.4× · PEG 1.17 85% evidence | 18.7/20 RS sector 4.7% · RS bench 36.7% · 1Y 48.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 20 + 11.2 + 18.7 = 72.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Amanta Healthcare Ltdthis pageAMANTA | 39.1/100Thin evidence · provisional57% evidence | BREAKING OUT | 5.9/35 Revenue 7.1% · PAT -8.3% · OPM change -1.7 pp 95% evidence | 13.2/25 ROCE 11.6% · OPM 21.1% 95% evidence | 10.0/20 P/E 39.6× · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 5.9 + 13.2 + 10 + 10 = 39.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Amanta Healthcare Ltd's share price today?
Amanta Healthcare Ltd trades at ₹156, +11.8% over the past year. The company is valued at ₹607 Cr. The stock sits at 73% of its 52-week range of ₹96–₹179, +13.9% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 13 weeks in. — as of 14 August 2026.
What were Amanta Healthcare Ltd's latest quarterly results?
Amanta Healthcare Ltd reported revenue of ₹68.8 Cr and net profit of ₹3.3 Cr for the Jun 26 quarter. Revenue rose 5.3% and profit fell 5.7% year on year. Earnings per share were ₹0.85. The operating margin was 21.1%, 1.7 pp lower than a year earlier. — as of 14 August 2026.
What is Amanta Healthcare Ltd's revenue?
Amanta Healthcare Ltd reported revenue of ₹68.8 Cr in the Jun 26 quarter, +5.3% year on year. For the full FY26 fiscal year, revenue was ₹288 Cr (+4.7%). Over the last 6 years revenue compounded at 7.8% a year. — as of 14 August 2026.
What is Amanta Healthcare Ltd's profit?
Amanta Healthcare Ltd earned ₹3.3 Cr of net profit in the Jun 26 quarter, −5.7% year on year. Full-year FY26 profit was ₹15.0 Cr. The operating margin ran 21.1% in the latest quarter. — as of 14 August 2026.
What is Amanta Healthcare Ltd's market cap?
Amanta Healthcare Ltd's market capitalisation is ₹607 Cr at a share price of ₹156. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 14 August 2026.
What is Amanta Healthcare Ltd's P/E ratio?
Amanta Healthcare Ltd trades at a P/E of 39.6×, at the 81st percentile of its own 1-year range, against a long-run median of 33.6×. This is a comparison with the stock's own history, not a value call — as of 14 August 2026.
Does Amanta Healthcare Ltd pay a dividend?
No — Amanta Healthcare Ltd has recorded a dividend payout of 0% of profit in each of its last 7 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 14 August 2026.
Is Amanta Healthcare Ltd overvalued?
On its own history, Amanta Healthcare Ltd looks expensive: its P/E of 39.6× sits at the 81st percentile of its 1-year range (long-run median 33.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 14 August 2026.
Is Amanta Healthcare Ltd growing?
Not right now — Amanta Healthcare Ltd's latest numbers are shrinking: latest-quarter revenue +5.3% year on year, profit −5.7%, and the margin −1.7 pp at 21.1%. The earnings engine currently reads: deteriorating — as of 14 August 2026.
How is Amanta Healthcare Ltd performing?
Amanta Healthcare Ltd is in a confirmed uptrend, 13 weeks in. Its latest quarter's revenue rose 5.3% and profit fell 5.7% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 27 weeks. This describes what the data did, not a rating. — as of 14 August 2026.
Is Amanta Healthcare Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 13 of stage 2), trading +13.9% versus its 200-day average and at 73% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 14 August 2026.
Is Amanta Healthcare Ltd beating the market?
On recent form, yes — Amanta Healthcare Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 27 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 11 months the stock moved +12% against the NIFTY 500's +1% — ahead of the index over the full window. — as of 14 August 2026.
Will Amanta Healthcare Ltd's share price go up?
This page publishes no price forecast for Amanta Healthcare Ltd. What it measures instead: the share price is ₹156, the price is in a confirmed uptrend 13 weeks in. Its P/E of 39.6× sits at the 81st percentile of its own 1-year range. — as of 14 August 2026.
Who owns Amanta Healthcare Ltd?
Promoters hold 63.8% of Amanta Healthcare Ltd, foreign institutions 0.4%, domestic institutions 12.9% and the public 22.8% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 14 August 2026.
Does Amanta Healthcare Ltd have too much debt?
It carries real leverage — Amanta Healthcare Ltd's debt-to-equity is 1.11, and operating profit covers the interest bill 3×. FY26 borrowings were ₹244 Cr against equity of ₹220 Cr. Read the returns on this page with that leverage in mind — as of 14 August 2026.
What is Amanta Healthcare Ltd's capex?
Amanta Healthcare Ltd spent ₹105 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹84.0 Cr, with ₹82.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 14 August 2026.
What is Amanta Healthcare Ltd's cash flow?
Amanta Healthcare Ltd generated ₹48.0 Cr of operating cash flow in FY26 and ₹−36.0 Cr of free cash flow after ₹84.0 Cr of capital spending. Reported profit that year was ₹15.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 14 August 2026.
Is Amanta Healthcare Ltd's profit real cash?
Yes — over the last 3 fiscal years, 528% of Amanta Healthcare Ltd's reported profit arrived as operating cash. Though the latest year ran at 320% — the trend is the thing to watch. In FY26, operating cash was ₹48.0 Cr against reported profit of ₹15.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 14 August 2026.
Where is Amanta Healthcare Ltd in its business cycle?
Amanta Healthcare Ltd's FY26 operating margin was 21.0%, against a 7-year band of 20.0%–23.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 21.1%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 14 August 2026.
What growth does Amanta Healthcare Ltd's price assume?
At its price on 13 June 2026, Amanta Healthcare Ltd was priced for profit growth of about 22.7% a year. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 14 August 2026.
What could break the Amanta Healthcare Ltd story?
Biggest watch item: the P/E sits at the 81st percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 14 August 2026.
Is Amanta Healthcare Ltd a stock worth studying right now?
This is not investment advice. The machine read: Amanta Healthcare Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 14 August 2026.